原发性肝癌组织生长激素受体的表达

THE EXPRESSIONS OF GROWTH HORMONE RECEPTOR IN HEPATOCELLULAR CARCINOMA

为探讨重组人生长激素 (rhGH)在肝癌患者中的适用问题 ,采用放射配体法对 32例原发性肝癌 (HCC)组织进行了生长激素受体 (GHR)的检测。结果在 2 8例HCC组织检测到GHR ,GHR受体结合容量 (RT)为 (18 430 0± 4 16 33)fmol/mg蛋白 ,平衡解离常数 (Kd)为 (0 6 432± 0 196 1)nmol/L ,与正常肝组织相比 ,其RT降低 (P <0 0 5 ) ,Kd无显著性改变 (P >0 0 5 ) ;HCC组织GHR的结合容量与肿瘤大小呈负相关 ,而与肿瘤分化程度、患者是否合并肝硬化无明显相关 ;有 4例肝癌组织未检测到GHR存在。研究提示 :大多数原发性肝癌组织仍表达低水平GHR ,在其功能未明的情况下 ,rhGH在肝癌患者中的使用应慎重。

In order to investigate if the recombinant human growth hormone(rhGH) is suitable for hepatocellular carcinoma(HCC) treatment,we used radioreceptor assays to detect if growth hormone receptor(GHR) was presented in 32 HCC tissues.The results showed that the growth hormone specific singular binding site,namely GHR,was detected in 28 cases. The binding capacity(R T ) of GHR was 18 4300±4 1633fmol/mg.protein and affinity constant(Kd) was 0 6432±0 1961nmol/L R T was lower ( P <0 05) compared with the normal liver tissue, but Kd did not show any difference ( P >0 05). The R T of the GHR was negatively correlated to the tumor's size,but was not correlated with differentiation of tumor, or the co existence of cirrhosis,GHR was absent in 4 cases. This study showed that the majority of the HCC tissue still express a low level of GHR. Before their functions are well understood, rhGH should be very carefully used in HCC patients.